Subscribe | Email Us | CFP Books | Letters to the Editor
About us
"WE BELIEVE"
100% Freshly-Extracted All-Natural Health Juice








Caruba: Professional Writing Services



Costa Rica Homes for Sale



Pursuant to Title 17 U.S.C. 107, other copyrighted work is provided for educational purposes, research, critical comment, or debate without profit or payment. If you wish to use copyrighted material from this site for your own purposes beyond the 'fair use' exception, you must obtain permission from the copyright owner.

Views are those of authors and not necessarily those of Canada Free Press. Content is Copyright 1997-2014 the individual authors.

Site Copyright 1997-2014 Canada Free Press.Com Privacy Statement


Powered by ExpressionEngine



"These investments are good for Canada and good for Canadians."

Statement - GlaxoSmithKline invests $12 Million in Canada for Influenza Research

Author
- Guest Column  Thursday, February 23, 2012
| Print friendly | Email Us

OTTAWA,  - Rx&D President Russell Williams made the following statement today about GlaxoSmithKline plc’s new funding of $12 Million to support an additional three-years of research to monitor seasonal influenza vaccine effectiveness in the elderly.

“Today’s announced investment by GlaxoSmithKline will help advance research already undertaken by supporting the tracking of the incidence and severity of diseases in elderly adults hospitalized with influenza across Canada. This funding will ensure key infrastructure will continue as surveillance research will be conducted in 40 hospitals across Canada comprising approximately 17,000 adult acute care beds, including sites in New Brunswick, Nova Scotia, Quebec, Ontario, Manitoba and British Columbia.”

“This announcement reflects the shared commitment by Canada’s research-based pharmaceutical industry to work with partners to invest in the health and prosperity of Canadians.”

“It is by working together that we can secure Canada’s position as a world leader in developing and delivering new health care solutions to people across Canada and throughout the world. Creating a more favourable environment for investment, by improving Canada’s intellectual property and access regimes, would help secure additional life sciences investments in Canada by the innovative pharmaceutical sector. These investments are good for Canada and good for Canadians.”

About Rx&D

Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents 15,000 men and women working for 50 member companies and invests more than $1 billion in research and development each year to fuel Canada’s knowledge-based economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.

Items of notes and interest from the web.